Ocugen, Inc. (OCGN) Stock Price & Analysis
Ocugen, Inc. (OCGN) fell 1.59% to USD 1.24 as of June 10, 2026 at 01:53 UTC, according to Nexqual real-time market data.
OCGN last closed at USD 1.26; the session ranged USD 1.22–1.31 on volume of 4,544,782 shares. Market capitalization is $419.77M, with a 52-week range of USD 0.9–2.73 (NCM). Source: Nexqual, June 10, 2026 at 01:53 UTC.
Key Statistics (as of June 10, 2026 at 01:53 UTC)
| Price | USD 1.24 |
|---|---|
| Change | ▼ 1.59% (down) |
| Previous Close | USD 1.26 |
| Open | USD 1.27 |
| Day Range | USD 1.22 – 1.31 |
| 52-Week Range | USD 0.9 – 2.73 |
| Volume | 4,544,782 shares |
| Market Cap | $419.77M |
| Exchange | NCM |
Technical Analysis (OCGN)
Nexqual's technical model rates OCGN "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 01:53 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 33.32 (neutral) |
| vs SMA50 | Below (USD 1.58) |
| MACD | -0.09 (negative) |
Analyst Ratings (OCGN)
Wall Street analysts rate OCGN "Strong Buy" based on 7 analysts, with a mean price target of USD 11.43 (range USD 7–22), per Nexqual as of June 10, 2026 at 01:53 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 11.43 |
| High Target | USD 22 |
| Low Target | USD 7 |
| Buy / Hold / Sell | 7 / 0 / 0 |
Earnings (OCGN)
| Next Earnings Date | 2026-07-30 |
|---|---|
| EPS Estimate | USD -0.05 |
| Revenue Estimate | $883,330 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.06 vs est -0.05 ▼ miss |
| 2025-12-31 | USD -0.06 vs est -0.06 ▼ miss |
| 2025-09-30 | USD -0.07 vs est -0.06 ▼ miss |
| 2025-06-30 | USD -0.05 vs est -0.06 ▲ beat |
Source: Nexqual, June 10, 2026 at 01:53 UTC.
Financials & Fundamentals (OCGN)
| Total Revenue | $4.46M |
|---|---|
| Revenue Growth (YoY) | +3.50% |
| Gross Margin | +0.00% |
| Operating Margin | -1163.67% |
| Profit Margin | +0.00% |
| ROE | -660.00% |
| Debt / Equity | 573.58 |
| Current Ratio | 1.86 |
| Total Cash | $31.86M |
| Total Debt | $33.30M |
| Free Cash Flow | $-33.67M |
Source: Nexqual, June 10, 2026 at 01:53 UTC.
Financial Health Score (OCGN)
Nexqual rates Ocugen, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 01:53 UTC.
| Growth | Solid — Revenue +9% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Critical — $32M cash vs $33M debt |
| Cash Flow | Weak — FCF negative: -$34M, burning cash |
| Efficiency | Critical — ROE -660%, ROA -68.2% |
Ownership (OCGN)
| Insider Ownership | +1.68% |
|---|---|
| Institutional Ownership | +34.10% |
| Shares Outstanding | 338.52M |
| Float | 316.86M |
| Short % of Float | +24.65% |
Source: Nexqual, June 10, 2026 at 01:53 UTC.
Leadership (OCGN)
Ocugen, Inc. is led by Shankar Musunuri (age 61), Co-Founder, CEO & Chairman, per Nexqual as of June 10, 2026 at 01:53 UTC.
| Co-Founder, CEO & Chairman | Shankar Musunuri (age 61) |
|---|---|
| Chief Scientific Officer and Head of Research & Development | Arun Upadhyay (age 43) |
| CFO & Principal Accounting Officer | Rita Johnson-Greene (age 48) |
| Executive Vice President of Operations | Paul Staid |
Major Backers & Investors (OCGN)
Notable institutional backers of Ocugen, Inc. include Millennium Management, Marshall Wace LLP, UBS Group AG, according to Nexqual as of June 10, 2026 at 01:53 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Millennium Management | 4.06% |
| Marshall Wace LLP | 2.38% |
| UBS Group AG | 2.15% |
| RTW Investments LP | 1.97% |
| Ikarian Capital, LLC | 1.17% |
| Qube Research & Technologies Ltd | 1.11% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 8.34% |
| State Street | 5.3% |
| BlackRock | 2.51% |
| Geode Capital | 1.25% |
Source: Nexqual, June 10, 2026 at 01:53 UTC.
From Ocugen, Inc.'s Latest SEC 10-K Filing (filed 2026-03-04)
Key Strengths & Strategy (as disclosed to the SEC)
- Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health.
- It is involved in the development of OCU200, a novel recombinant fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage for the repair of knee cartilage injuries in adult.
- In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine.
Partnerships
- It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BNGO | Bionano Genomics, Inc. | USD 1.16 | ▼ 0.85% |
| SNDL | SNDL Inc. | USD 1.46 | ▲ 2.82% |
| VXRT | Vaxart, Inc. | USD 0.58 | ▼ 6.45% |
| SENS | Senseonics Holdings, Inc. | USD 7.43 | ▲ 11.39% |
| JAGX | Jaguar Health, Inc. | USD 2.82 | ▲ 0.71% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 01:53 UTC. This page is informational and not investment advice.